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Oral isotretinoin has had a major positive impact on the
lives of countless patients since its introduction in the early
1980s. Of course, we feel it is imperative to provide oral iso-
tretinoin to our patients in the safest manner possible. But we
also believe that instituting increasingly restrictive programmes
around the use of the drug may not be the optimal approach
in view of the limitations of such programmes. In particular,
restrictive programmes such as iPLEDGE may have reached the
limit of influencing human behaviour. More restrictive pro-
grammes, apart from mandated use of injectable long-acting
contraceptives, cannot prevent unintended pregnancies result-
ing from failure to use contraceptives appropriately. We think
that the situation is similar for Europe. Until there are
improved options for the patients who are now isotretinoin
candidates, it is important to take a balanced approach that
allows for appropriate use of this important drug. We are sad-
dened that the article by Shin et al. suggests that women selec-
tively may be receiving fewer prescriptions for isotretinoin,
despite the fact that prescription levels for males have
remained relatively constant. We agree with a recent editorial
by Maloney and Stone15 suggesting that a team or committee
evaluation of prescribing patterns and fetal exposure would be
a valuable addition to the current system with the goal of
improving patient access and outcomes.
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MADAM, We thank Professors Thiboutot, Gollnick, Bettoli,
Dre´no, Kang, Leyden, Shalita and Torres1 for the Global Alliance
to Improve Outcome in Acne, for their comments on our arti-
cle.2 Their letter points out an important aspect of having acne
and the effectiveness of isotretinoin in treating this disorder.
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Thiboutot et al. draw attention to the effectiveness of iso-
tretinoin and the psychological burden of acne. Most patients
with acne are in the age group of 12–20 years and approxi-
mately 50% are females of childbearing potential.
The effectiveness of isotretinoin was not considered the
subject of discussion in our paper. We agree that the effective-
ness of isotretinoin is well acknowledged3 and the benefit–risk
balance is considered to be positive, provided that the preg-
nancy prevention programme (PPP) is adhered to.
The major concern for isotretinoin is its teratogenicity.
The risk of congenital anomalies with isotretinoin should
be minimized in a way such that it can still be prescribed for
the treatment of acne with the least restraints. This can only
be achieved when both healthcare professionals and patients
are aware of – and are compliant with – the PPP. By creating
awareness of noncompliance with the PPP, it is hoped that
prescribers, pharmacists and patients will adjust their routine
and take responsibility for adhering to the PPP.
The iPLEDGE programme in the U.S.A. contains a PPP with
stricter rules and requirements compared with the previous
programme ‘System to Manage Accutane-Related Teratogenic-
ity’ (SMART). Research showed that iPLEDGE did not decrease
the pregnancy rate4 compared with the rate while SMART was
in place. This information might suggest that other actions
might be necessary to improve the prevention of pregnancies
and the adherence to the programme.
We agree with Thiboutot et al. that the emotional aspect of
acne should not be trivialized; however, the retinoid embry-
opathy might also have a major impact, as well as the emo-
tional burden of induced or spontaneous abortion in patients
getting pregnant while using isotretinoin. Based on the current
experience with the programmes (PPPs), we also would like
to support the suggestion of Maloney and Stone5 to develop a
multidisciplinary team that will review all available data to
detect where the system fails and where it over-regulates. Our
joint aim is to keep an effective treatment for acne on the
market while causing the least restraints but with a high com-
pliance for measures to minimize the risk of congenital anom-
alies due to isotretinoin.
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Annual Evidence Based Update Meeting 2012: Acne and
Rosacea
Thursday 10th May 2012: 10am-4.15pm
Location: Holywell Park, Loughborough
Organiser: Professor Hywel Williams
Cost: £90 ⁄£100
For further information please contact: Carron Layfield on
carron.layfield@nottingham.ac.uk
National Skin Centre Dermatology Update 2012 May 11th–
13th 2012
Meritus Mandarin Orchard, Singapore.
For further information contact:
Conference Secretariat Mrs Alice Chew
National Skin Center (S) Pte Ltd
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